C R Bard Inc (BCR) : Jlb Associates Inc scooped up 932 additional shares in C R Bard Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 21, 2016. The investment management firm now holds a total of 46,702 shares of C R Bard Inc which is valued at $10,741,460.C R Bard Inc makes up approximately 2.95% of Jlb Associates Inc’s portfolio.
Other Hedge Funds, Including , Ls Investment Advisors boosted its stake in BCR in the latest quarter, The investment management firm added 1,340 additional shares and now holds a total of 19,434 shares of C R Bard Inc which is valued at $4,469,820. C R Bard Inc makes up approx 0.30% of Ls Investment Advisors’s portfolio.Acadian Asset Management boosted its stake in BCR in the latest quarter, The investment management firm added 69,018 additional shares and now holds a total of 431,951 shares of C R Bard Inc which is valued at $100,407,010. C R Bard Inc makes up approx 0.50% of Acadian Asset Management’s portfolio.Davis R M Inc reduced its stake in BCR by selling 4,246 shares or 2.21% in the most recent quarter. The Hedge Fund company now holds 187,911 shares of BCR which is valued at $43,574,682. C R Bard Inc makes up approx 2.09% of Davis R M Inc’s portfolio.Parasol Investment Management reduced its stake in BCR by selling 30 shares or 8.65% in the most recent quarter. The Hedge Fund company now holds 317 shares of BCR which is valued at $73,509. C R Bard Inc makes up approx 0.08% of Parasol Investment Management’s portfolio.Curbstone Financial Management Corp reduced its stake in BCR by selling 1,990 shares or 27.68% in the most recent quarter. The Hedge Fund company now holds 5,200 shares of BCR which is valued at $1,242,800. C R Bard Inc makes up approx 0.41% of Curbstone Financial Management Corp’s portfolio.
C R Bard Inc opened for trading at $223.94 and hit $226 on the upside on Thursday, eventually ending the session at $224.25, with a gain of 0.27% or 0.6 points. The heightened volatility saw the trading volume jump to 7,15,830 shares. Company has a market cap of $16,442 M.
On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.
Many Wall Street Analysts have commented on C R Bard Inc. C R Bard Inc was Downgraded by BofA/Merrill to ” Neutral” on Jul 8, 2016. Company shares were Reiterated by Barclays on May 24, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 224 from a previous price target of $212 .Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 212 from a previous price target of $195 .
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.